Matches in Nanopublications for { ?s ?p "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 17 of
17
with 100 items per page.
- NP267330.RAdLOPuHXawfbwGKFVGN1_VoTv24DMtYHA7zQOaSHr1OQ130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP267330.RAdLOPuHXawfbwGKFVGN1_VoTv24DMtYHA7zQOaSHr1OQ130_provenance.
- NP468870.RA_ai9L6QGF8fo6L9rHEPrZufj6DfQBxXFitXD21GV3fo130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468870.RA_ai9L6QGF8fo6L9rHEPrZufj6DfQBxXFitXD21GV3fo130_provenance.
- NP588218.RAZaxyL01qqdT3d0btZHn2IZDwgdH-Gzo6_JjMoErSYb0130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588218.RAZaxyL01qqdT3d0btZHn2IZDwgdH-Gzo6_JjMoErSYb0130_provenance.
- assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP651909.RAwwHl8Mvm3ALMCWQ630cN4zjaYFvEqotteh29HBrpDmU130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651909.RAwwHl8Mvm3ALMCWQ630cN4zjaYFvEqotteh29HBrpDmU130_provenance.
- NP664671.RASZsRYsUuLTkQSiLgSJzQrG2AOXaUZ3poUuUCCcdqO6A130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP664671.RASZsRYsUuLTkQSiLgSJzQrG2AOXaUZ3poUuUCCcdqO6A130_provenance.
- NP646488.RAcuoY0k6WJ8ogKyhigd8Btb0W99F0fB-CAQQ9r13g3ps130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646488.RAcuoY0k6WJ8ogKyhigd8Btb0W99F0fB-CAQQ9r13g3ps130_provenance.
- assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP865361.RAjzllOOhMSu6BmE1hDPzx_pEXkon34S4Evz8K03Gt4gM130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865361.RAjzllOOhMSu6BmE1hDPzx_pEXkon34S4Evz8K03Gt4gM130_provenance.
- NP741445.RAq-CjVwlrMDPSb3nJmUN_5oZtws6fOKWO5itcmQlXpEk130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741445.RAq-CjVwlrMDPSb3nJmUN_5oZtws6fOKWO5itcmQlXpEk130_provenance.
- NP741439.RAHooL9uaSnXitWhf16OS6Qgh2ThdKZTmYRBmqQYnsaGQ130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741439.RAHooL9uaSnXitWhf16OS6Qgh2ThdKZTmYRBmqQYnsaGQ130_provenance.
- NP741444.RAK8xGmJ25IPUNfoDLd2xeN1lYMJZxAzh2XTUzk2NSZ5U130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741444.RAK8xGmJ25IPUNfoDLd2xeN1lYMJZxAzh2XTUzk2NSZ5U130_provenance.
- NP741441.RA4T5fhsicnj5mV5wTXRYy93H1gzlOmYbRcVvvVWZrnBE130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741441.RA4T5fhsicnj5mV5wTXRYy93H1gzlOmYbRcVvvVWZrnBE130_provenance.
- NP741446.RAxN5seDERYOiOu2Iz2Fe9q9jEuUC7lqz2ZtkAPb0t7kE130_assertion description "[KRAS and BRAF mutations occur in colorectal cancers (CRCs) and are considered mutually exclusive methods of activating the RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741446.RAxN5seDERYOiOu2Iz2Fe9q9jEuUC7lqz2ZtkAPb0t7kE130_provenance.